Efficacy and Safety of VICRIVIROC in HIV-Infected Treatment-Naïve Subjects (Study P04875)
Status:
Completed
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
Vicriviroc (vye-kri-VYE-rock) is an investigational drug (not yet approved by Government
Regulatory Authorities for commercial use) that belongs to a new class of drugs, called CCR5
receptor blockers. This group of drugs blocks one of the ways HIV enters T-cells (the cells
that fight infection). Previous smaller studies in HIV treatment-experienced patients, have
shown that vicriviroc is safe and effective. The purpose of this study is to evaluate the
virologic efficacy of vicriviroc combined with ritonavir-boosted Reyataz® in HIV-infected
treatment-naïve subjects.